Q4 2024 Earnings Call Transcript March 20, 2025 TELA Bio, Inc. beats earnings expectations. Reported EPS is $-0.23, ...

Because LiquiFix is indicated for use only with synthetic mesh, we’ve been able ... engaging discussion on paraesophageal hernia repairs. Our long-term ventral and inguinal data were also ...

The global hernia mesh devices market was valued at USD 4.6 billion in 2022 and is expected to reach USD 6.5 billion by 2032, reflecting a Compound Annual Growth Rate (CAGR) of 3.4%. Inguinal hernias ...

TELA BIO ($TELA) posted quarterly earnings results on Thursday, March 20th. The company reported earnings of -$0.23 per share, missing estimates of -$0.23 by $0.00 ...

The company plans to launch new products, including larger OVATEX PRS products and long-term resorbable hernia products. Tela Bio expects to maintain flat operating expenses compared to 2024 and ...

The company plans to launch new products, including larger OVATEX PRS products and long-term resorbable hernia products. Tela Bio expects to maintain flat operating expenses compared to 2024 and aims ...

Hernia mesh can cause serious complications that may require revision surgeries. Thousands of hernia mesh lawsuits have already been filed, helping victims pursue justice and compensation for their ...